ACT Brief: Digital Recruitment Strategies, Tremfya’s Long-Term PsA Results, and Agentic AI’s Enterprise Impact

This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.

• In a new video interview, Trialbee’s Christian Bullock explains how the company determines whether platforms like TikTok, Reddit, or Spotify are appropriate for patient recruitment. He outlines three core criteria: whether the platform’s audience and behaviors align with the trial’s target population, whether its content formats support effective creative execution, and whether the platform can deliver high-quality referrals even at lower volumes. Bullock notes that while these channels may reach smaller pools of patients or caregivers, they often produce more intentionally engaged participants—making them valuable additions to modern recruitment strategies.
• Johnson & Johnson has released 48-week findings from the Phase IIIb APEX trial, showing that Tremfya continues to deliver durable symptom relief and inhibit structural progression in biologic-naïve psoriatic arthritis patients. The long-term data support J&J’s ongoing sBLA, with improvements maintained across dosing schedules and continued alignment with the therapy’s established safety profile. The results reinforce Tremfya’s potential to address both early joint involvement and patients already showing radiographic damage.
• And a new Pharm Exec feature examines how the Veeva–Salesforce split is accelerating decisions around CRM strategy—just as agentic AI begins to enter commercial workflows. As organizations evaluate new platforms, experts say AI agents will soon automate key processes across customer engagement, forecasting, scheduling, and content delivery. Over the next several years, these autonomous tools are expected to dramatically expand field force capabilities, streamline operations, and reshape how life sciences companies support healthcare providers.

That’s all for today’s ACT Brief. Join us next time for more updates shaping clinical operations and drug development. Thanks for listening.